Related Experiment Video
Updated: Feb 7, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
Published on: December 27, 2013
Charge-reversal-functionalized PLGA nanobubbles as theranostic agents for ultrasonic-imaging-guided combination
1Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, China. liuyiyao@uestc.edu.cn liuyiyao@hotmail.com.
Abstract:
The efficacy of cancer chemotherapy can be generally restrained by the multiple drug resistance (MDR) of tumors, which is typically attributed to the upregulation of ATP-binding cassette (ABC) transporter proteins, such as P-glycoprotein (P-gp). There is an urgent need to present innovative strategies to reverse MDR and enhance the therapeutic efficacy of chemotherapeutic agents in biomedical applications. Here, we report a novel nanosystem of charge-reversal-functionalized PLGA nanobubbles (denoted as Dox-NBs/PPP/P-gp shRNA) for the co-delivery of Dox and P-gp shRNA for the reversal of drug resistance and for ultrasonic-imaging-guided tumor therapy. 1H NMR, FT-IR, SEM, DLS, and UV-vis spectroscopy characterizations were conducted to determine the structure, morphology, and composition of the as-prepared nanobubbles. Dox-NBs/PPP/P-gp shRNA exhibited an average diameter of about 300 nm with good dispersity, biocompatibility, and pH-responsive release properties through the charge-reversal process. The in vitro experiments showed that Dox-NBs/PPP/P-gp shRNA nanobubbles could co-deliver Dox and P-gp shRNA into tumor cells and could effectively suppress P-gp expression, leading to enhanced overall therapeutic effects against MCF-7/MDR cells by restraining the drug efflux. An in vivo antitumor assay revealed an approximately 65% inhibition rate of Dox-NBs/PPP/P-gp shRNA against MCF-7/ADR tumors in tumor-bearing nude mice. Both the in vitro and in vivo toxicity results indicated the Dox-NBs/PPP/P-gp shRNA are highly biocompatible with reducing side-effects and have negligible systemic toxicity in the in vivo therapy of resistant cancers by combining with a chemotherapeutic agent and P-gp knockdown. Furthermore, the in vivo imaging data substantiated that the functionalized nanobubbles could be used as an efficient contrast agent for the ultrasonic imaging of solid tumors. This works highlights the great potential of Dox-NBs/PPP/P-gp shRNA nanobubbles for enhanced imaging-guided combination therapy for overcoming MDR.
Insights
This study introduces novel nanobubbles that deliver chemotherapy and P-gp shRNA to overcome cancer drug resistance. The nanobubbles show enhanced tumor inhibition and imaging capabilities, offering a promising strategy for resistant cancer therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Multiple drug resistance (MDR) in cancer limits chemotherapy efficacy, often due to ATP-binding cassette (ABC) transporter proteins like P-glycoprotein (P-gp).
- Innovative strategies are needed to reverse MDR and improve cancer treatment outcomes.
Purpose of the Study:
- To develop and evaluate novel charge-reversal-functionalized PLGA nanobubbles (Dox-NBs/PPP/P-gp shRNA) for co-delivering doxorubicin (Dox) and P-gp shRNA.
- To assess the potential of these nanobubbles for drug resistance reversal, ultrasonic-imaging-guided tumor therapy, and overcoming MDR in cancer.
Main Methods:
- Characterization of nanobubbles using techniques like 1H NMR, FT-IR, SEM, DLS, and UV-vis spectroscopy.
- In vitro evaluation of drug delivery, P-gp expression suppression, and therapeutic effects on MCF-7/MDR cells.
- In vivo antitumor assays in tumor-bearing nude mice and assessment of biocompatibility and systemic toxicity.
- In vivo ultrasonic imaging to evaluate nanobubble contrast agent properties.
Main Results:
- The Dox-NBs/PPP/P-gp shRNA nanobubbles demonstrated pH-responsive release, good dispersity, and biocompatibility.
- Co-delivery of Dox and P-gp shRNA effectively suppressed P-gp expression and drug efflux in vitro, enhancing therapeutic effects.
- In vivo studies showed a 65% inhibition rate against MCF-7/ADR tumors with reduced side effects and negligible systemic toxicity.
- The nanobubbles served as an efficient contrast agent for ultrasonic imaging of solid tumors.
Conclusions:
- The developed nanobubbles are effective in co-delivering chemotherapy drugs and P-gp shRNA to overcome MDR.
- This approach significantly enhances antitumor efficacy and offers potential for imaging-guided combination therapy in resistant cancers.
- The nanocarrier system exhibits high biocompatibility and reduced systemic toxicity, highlighting its therapeutic promise.
More Related Videos
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combining Functions
Formal Charges
Ions and Ionic Charges
Atomic Radii and Effective Nuclear Charge
Electric Charges
The English physicist William Gilbert studied the phenomenon of static electricity in...

